Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission
Most Cited Paper
in Acute Myeloid Leukemia Research
18 Months Post-Publication
Class of 2026
“Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
NPM1-mutated AML · Allogeneic transplant in first complete remission · Measurable residual disease (MRD) · quantitative reverse transcription polymerase chain reaction · FLT3-internal tandem duplication · postinduction MRD status · peripheral blood NPM1 MRD · Overall survival · FLT3 allelic ratio · NCRI-AML17 trial · UK National Cancer Research Institute AML19 · molecular MRD · Induction chemotherapy · MRD-positive patients · MRD-negative patients · transplant selection criteria
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459